The early-2026 GLP-1 market stopped feeling stable almost overnight. Regulators sent warning letters to dozens of compounding-adjacent companies, Novo Nordisk’s March settlement moved several large platforms away from compounded semaglutide, and Lilly’s oral orforglipron rollout added a cheaper brand-name wrinkle.

That shake-up is exactly why I put this list together. Choosing a GLP-1 provider right now means asking sharper questions than you would have a year ago.

What I Looked At

Before picking any provider, I weighed these factors:

• Pharmacy transparency. Is the dispensing pharmacy named? Is it 503A certified? Do they publish lot tracking or purity results?
• Pricing honesty. No buried fees. I want the real monthly number.
• Physician involvement. Rubber-stamp questionnaires don’t count. I want a real clinician reviewing your file.
• Shipping reliability. Overnight or fast tracked, confirmed at checkout.
• Regulatory standing. LegitScript certification, HIPAA compliance, no active FDA warning letters.
• Scope of care. Does the platform offer monitoring, or just a prescription and a wave goodbye?

One honest note before we go further: compounded GLP-1 medications are not FDA-approved. They can legally be prescribed and dispensed by licensed 503A pharmacies, but “compounded” is not the same as the branded, FDA-approved versions. Keep that distinction in mind with any provider on this list.

The 7 Providers

1. HealthRX

Compounded semaglutide starting at $99 a month, tirzepatide at $149, shipped overnight to all 50 states for free. That pricing alone gets my attention, because most telehealth platforms charge meaningfully more for the same molecule class. But price is only worth something if the sourcing holds up.

HealthRX dispenses through Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-by-lot tracking from bench to your door. The pharmacy is LegitScript certified (cert number 50087439). A US board-certified physician reviews your health assessment within about 24 hours, and medication ships overnight after approval. No contracts, no hidden fees, and the pricing page shows you exactly what you’ll pay before you commit.

The efficacy figures they cite come from published clinical trials: tirzepatide showed roughly 21% average body weight reduction at 72 weeks in SURMOUNT-1, and semaglutide roughly 15% at 68 weeks in STEP 1. Those are trial results, not HealthRX’s own claims, but they’re the most honest benchmarks available.

For most people weighing cost, pharmacy accountability, and speed of access, this is the strongest overall package right now.

2. FormBlends

FormBlends is worth a serious look if published purity data matters to you, or if you want GLP-1 treatment alongside a broader peptide catalog from one clinical team. Most GLP-1 telehealth brands stop at weight loss. FormBlends also carries recovery, longevity, and cognitive peptides under the same physician-oversight model, which is genuinely uncommon.

On the GLP-1 side, the platform dispenses through an FDA-registered 503A compounding pharmacy and publishes per-product testing: HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility results with named numbers attached. That level of transparency is rare in this space.

The tradeoff is price. Semaglutide is priced at roughly $299 per vial and tirzepatide at roughly $349, both of which clear HealthRX’s entry-level figures by a meaningful margin. Coverage reaches 47 states, not all 50. For someone who prioritizes documented lab verification or needs a one-stop provider for GLP-1s plus other peptides, FormBlends earns its spot. For straight cost-per-month value, HealthRX edges it out.

3. Mochi Health

Mochi uses board-certified obesity-medicine clinicians, not just general practitioners, and that specialization shows in how the monitoring is structured. Monthly cost comes to around $99 for compounded semaglutide and approximately $199 for tirzepatide. The clinical check-ins are more frequent than on most cash-pay platforms, which suits people who want ongoing support rather than a set-it-and-forget-it prescription.

4. Hims & Hers

After the March 2026 Novo settlement, Hims & Hers moved off compounded semaglutide and shifted to branded medications. Injectable Wegovy is priced around $299 a month through the platform, oral options around $249, and Zepbound around $399. With insurance plus a manufacturer savings card, some patients pay as little as $0 to $25 monthly. Best fit for people with good insurance coverage who want a polished, well-known platform.

5. Ro Body

Ro charges roughly $39 for the first month of membership, then $74 to $149 going forward, with medications billed separately. Their prior-authorization team will work with your insurance to get branded GLP-1s covered, which is a real operational advantage for anyone who qualifies. Not the cheapest cash-pay option, but the insurance support is among the best in this category.

6. Henry Meds

Henry runs cash-pay compounded GLP-1s with fast shipping, typically 24 to 72 hours. First-month pricing lands around $179 to $249. The monitoring is lighter than Mochi’s, which some people prefer if they just want efficient access without frequent check-ins. Good for patients who are already working with an in-person doctor and need a cost-effective prescription source.

7. PlushCare

PlushCare is a full telehealth platform, not a GLP-1 specialist, and that breadth is actually useful here. Membership costs $19.99 a month, same-day visits are available, and branded GLP-1s are prescribed with insurance accepted. If you want one telehealth membership that covers GLP-1s, primary care, and mental health, PlushCare is the most versatile option on this list.

How to Choose

Start with two questions. First: are you paying cash, or do you have insurance that might cover a branded medication? If insurance is in play, Hims & Hers or Ro may get you to a lower real-world cost than any cash-pay compounded provider. Second: how much ongoing support do you want? Mochi and Calibrate build that in. Henry Meds and HealthRX assume more self-direction.

Pharmacy accountability matters more than most people realize. A named 503A facility with lot tracking is meaningfully different from a vague “licensed compounding partner.” That single detail is worth checking before you pay anything.

Common Questions

Does the March 2026 Novo Nordisk settlement mean compounded semaglutide is now illegal?

Not exactly. The settlement changed what certain large compounders could do, but licensed 503A pharmacies can still legally dispense compounded semaglutide when prescribed by a clinician. What shifted is which platforms can source and sell it at scale. Providers like HealthRX and Henry Meds operating through named 503A facilities remain on solid legal ground as of mid-2026.

What does 503A certification actually mean for a compounding pharmacy, and why does it matter here?

A 503A pharmacy compounds medications for individual patients under a valid prescription, operating under state board oversight and USP-797 sterile standards. It is not the same as FDA manufacturing approval. The designation matters because it sets enforceable quality minimums, including sterility and beyond-use dating requirements, that unregistered compounders are not held to.

If FormBlends publishes HPLC and mass spectrometry results, why would anyone choose a provider that does not?

Published testing is a strong signal, but it is not the only signal. Lot-by-lot tracking from a named 503A facility, as HealthRX uses through Manifest Pharmacy, is a different form of accountability. Cost matters too. FormBlends runs roughly $150 to $200 more per month than HealthRX. For many patients, the pricing gap outweighs the added documentation layer.

Which providers on this list are actually worth considering if my insurance covers branded GLP-1s?

Hims & Hers and Ro Body are the clearest fits. Hims & Hers lists Wegovy at $299 and Zepbound at $399, but manufacturer savings cards can bring out-of-pocket costs to near zero for eligible patients. Ro’s prior-authorization team actively works insurance on your behalf, which is a real time-saver if your plan requires documentation to approve coverage.

How do I know whether a telehealth GLP-1 provider has received an FDA warning letter?

FDA warning letters are public record and searchable at FDA.gov under the Warning Letters database. Search the company name or the pharmacy name. If a provider is vague about which compounding pharmacy they use, that makes this check impossible, which is itself a reason for caution. Every provider on this list either names its pharmacy or uses branded medications through licensed channels.

Sources

• FDA warning letters to compounding telehealth companies, early 2026 (FDA.gov)
• Novo Nordisk / FDA compounded semaglutide settlement, March 9 2026 (Reuters, FDA.gov)
• SURMOUNT-1 trial (tirzepatide, NEJM 2022)
• STEP 1 trial (semaglutide, NEJM 2021)
• LegitScript pharmacy certification database (LegitScript.com)
• USP-797 sterile compounding standards (USP.org)
• Lilly orforglipron launch pricing, LillyDirect (Eli Lilly press release, April 2026)